Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. natural immune system
Show results for
Products
Services

Companies

News
Articles
Books

Refine by
Date

  • Older

Natural Immune System Articles & Analysis

5 news found

AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

“We currently manage high-level BK viremia by reducing immunosuppressive therapy, which can help a patient’s immune system clear the virus, but this approach raises the risk that the immune system will attack and reject the graft. ...

ByKalaris


Intrommune Therapeutics Launches #PeanutAllergyStrong

Intrommune Therapeutics Launches #PeanutAllergyStrong

” Intrommune’s lead product in development, INT301, utilizes the oral mucosal immunotherapy platform (OMIT) to decrease allergic immune response in patients through daily tooth brushing. The product delivers allergenic proteins to areas of the oral cavity to naturally trigger an immune system response towards ...

ByIntrommune Therapeutics


Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection

Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection

VTP-200 utilizes Vaccitech’s ChAdOx (prime) and MVA (boost) platform to elicit an immune response against HPV. The platform has a differentiated ability to induce CD8+ T cells, cells of the immune system which naturally clear HPV infected cells in cervical tissue. ...

ByVaccitech plc


LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs

LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs

” Gamma-delta T cells are the natural surveillance cells of the immune system, continuously patrolling the human body for the identification and targeting of tumor cells. These cells bridge the innate with the adaptive immune system and are a largely untapped opportunity in cancer treatment. ...

ByLAVA Therapeutics N.V.


Actym Therapeutics Will Present Data at the 2019 Society for the Immunotherapy of Cancer (SITC) Annual Meeting

Actym Therapeutics Will Present Data at the 2019 Society for the Immunotherapy of Cancer (SITC) Annual Meeting

“Therapeutic targeting of many immune pathways is currently limited to a suboptimal, intratumoral (IT) route of administration. This is due to toxicities or lack of efficacy when systemically dosed, and will not be tractable in a metastatic disease setting. ...

ByActym Therapeutics

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT